Baricitinib is an effective treatment option for children and adolescents with atopic dermatitis, with no new safety signals identified.

Patients with CRSwNP have a high burden of SCS use and associated health care costs, especially when they have comorbid asthma.

Using GLI Global vs GLI Caucasian spirometry equations in pediatric patients aged 18 and younger was linked to significant changes in z-scores.

Upadacitinib was superior to dupilumab for the treatment of atopic dermatitis in the head and neck, trunk, upper limbs, and lower limbs.

Remdesivir treatment reduces the risk for 30-day COVID-19-related hospital readmission among all patients discharged alive from initial hospitalization.

Among health care personnel, influenza vaccination has not returned to 2019 levels, and COVID-19 vaccinations have been decreasing.

Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

RSV remains a major cause of hospitalization among children, according to a population-based Canadian Immunization Research Network study.

Exposures to fine particulate matter (PM2.5) and specific PM2.5 constituents during pregnancy is associated with increased odds of spontaneous preterm birth (sPTB).

Neonatal sepsis is more prevalent in Hispanic vs White infants, while overall and sepsis-related mortality rates are highest among Black infants.

Exposure to elexacaftor-tezacaftor-ivacaftor (ETI) is associated with metabolic syndrome (MetSyn) in patients with cystic fibrosis.

Treatment with montelukast was not associated with reduced symptom duration in adult outpatients with mild to moderate COVID-19 infection.